Fulvestrant/Fulvestrant Instructions for Use and Dosage

Fulvestrant (Fulvestrant) is a selective estrogen receptor degrader (SERD), mainly used to treat hormone receptor-positive advanced or metastatic breast cancer. Its administration method is intramuscular injection, and it is absorbed directly into the muscle tissue, allowing the drug to slowly enter the blood circulation and maintain a stable blood concentration. This method of administration can avoid variations in gastrointestinal absorption and first-pass effects of oral drugs, thereby ensuring that the drug reaches ideal therapeutic concentrations in the body.

The standard adult dosage is 500mg each timeUse two injections in divided injections, 250mg/5ml on each buttock. Each injection must be completed slowly, usually within 1 to 2 minutes, to reduce discomfort and local reactions at the injection site. In the initial treatment phase, the injection schedule is three injections on the 1st, 15th and 29th days to reach a stable therapeutic concentration as soon as possible, and then enter the maintenance phase with monthly injections. This dosage design not only ensures drug efficacy, but also maintains the stability of blood drug levels during long-term treatment, thereby prolonging disease control time.

For patients with moderate hepatic impairment, the recommended dose is adjusted to 250 mg each time, also following the intramuscular injection method and the same injection frequency. Since the liver is an important organ for drug metabolism, dose adjustment can help reduce the risk of drug accumulation in the body while ensuring that patients can tolerate treatment. In clinical practice, the injection process should be carried out under the guidance of medical personnel, and patients are advised to gently massage the injection area after the injection to help distribute the liquid evenly and reduce local pain.

In addition, patients need to regularly monitor liver function and blood indicators during treatment to ensure smooth drug metabolism and timely adjustment of treatment plans. Through standardized injections and scientific dose management, fulvestrant can provide patients with advanced breast cancer with a continuous, stable and safe endocrine therapy program, providing reliable support for clinical treatment.

Reference materials:https://medlineplus.gov/druginfo/meds/a607031.html